Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

POCATELLO – An Idaho State University alumnus has returned to Pocatello to address the high demand for mental health services ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly given its recent $14.6 billion acquisition of Intra-Cellular Therapeutics and ...